# Adaptimmune

其 TCR-T 产品 Tecelra（afamitresgene autoleucel）靶向滑膜肉瘤中的 MAGE-A4，是首个获批的工程化 TCR 细胞疗法，奠定了自体 TCR-T 类别，管线还包括 lete-cel（NY-ESO-1）及其他 MAGE-A4/PRAME 项目。

Source: https://cn.bioecon.ru/companies/adaptimmune/
Updated: 2026-07-11

- 国家: United Kingdom
- 代码: ADAP

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 继2025年7月出售细胞治疗资产（TECELRA、lete-cel、afami-cel、uza-cel）后，US WorldMeds支付$5500万首付款，另有最高$3000万里程碑付款 | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001104659-25-071009/tm2521829d1_8k.htm, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/R25.htm |
| 产能 | 截至2025年第二季度，商业化生产成功率为100%，无任何限制 | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001558370-25-003544/0001558370-25-003544.pdf, https://www.newsfilecorp.com/release/245279/Adaptimmune-Provides-Q4-and-Full-Year-2024-Business-Update, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm |
| 监管批准 | TECELRA（afamitresgene autoleucel）于2024年8月1日获美国FDA加速批准，用于治疗不可切除或转移性滑膜肉瘤成人患者 | https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/271/adaptimmune-receives-u-s-fda-accelerated-approval-of, https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001558370-25-003544/0001558370-25-003544.pdf, https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma |
| 生产基地 | 设施位于费城、波士顿及英国 | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001558370-25-003544/0001558370-25-003544.pdf, https://www.newsfilecorp.com/release/245279/Adaptimmune-Provides-Q4-and-Full-Year-2024-Business-Update |
| 员工人数 | 2025年第一季度裁员约29%，并计划在2025年7月交易完成后对剩余员工再裁减约62% | https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/content/0001104659-25-071009/tm2521829d1_8k.htm, https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings/xbrl_doc_only/2590, https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm |
| 营收 | 2025 年第二季度产品收入为 1110万美元；同期总收入为 1370万美元 | https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm |

独立来源: cancer.gov, fda.gov, newsfilecorp.com, sec.gov

## 技术

- [TCR 疗法（T 细胞受体工程化 T 细胞）](https://cn.bioecon.ru/technology/tcr-therapy/)